Isis Pharmaceuticals Inc., of Carlsbad, Calif., and Genzyme Corp., of Cambridge, Mass., a unit of Sanofi SA, reported two-year data from a Phase III long-term extension study showing that Kynamro (mipomersen) maintained robust reductions in LDL-C in patients, as well as reductions in all other Apo B-containing atherogenic lipoproteins measured, with a safety profile consistent with the Phase III studies.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter